9Bio News
9Bio Therapeutics is proud to announce a strategic investment from the Merck Digital Sciences Studio (MDSS) and CQDM. The funding will accelerate the development of 9Bio’s computationally guided discovery platform and pipeline of tumor-selective therapies.
9Bio Therapeutics and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are pleased to announce a collaborative $1.8 million initiative in targeted oncology therapies. The project has received significant support from the Government of Quebec, in the form of a $0.9 million grant through CQDM’s Partenar-IA program, in partnership with IVADO.
In partnership with TransBIOTech (Levis, QC), 9Bio Therapeutics has been awarded a $450,000 Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program, administered through the Natural Sciences and Engineering Research Council of Canada (NSERC) in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and Canadian Institutes of Health Research (CIHR).
9Bio Therapeutics is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two Quebec-based biotech companies. This funding will accelerate the preclinical development of highly targeted, safer cancer therapies, leveraging artificial intelligence (AI) and structural biology to redefine drug discovery.
9Bio Therapeutics is proud to announce its recognition at this year’s DEVTECH Life Sciences and Health Technologies Entrepreneurial Competition. This award, presented by Québec International and Québec VITAE, acknowledges the potential of 9Bio’s team and platform technology to develop conditionally active therapies targeting the tumor microenvironment.
9Bio Therapeutics is proud to announce its acceptance into the adMare BioInnovations National Therapeutics (Tx) Accelerator. This strategic partnership aims to advance 9Bio’s mission of developing targeted cancer therapies that prioritize patient safety and treatment efficacy.
9Bio Therapeutics is pleased to announce that it will receive $75,000 in funding from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to support the development of its lead program – a precision antibody-drug conjugate (ADC).